Quadrant Capital Group LLC Denali Therapeutics Inc. Transaction History

Quadrant Capital Group LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 08, 2024	BUY	$16.2 - $23.18 $194 - $278	12 Added 171.43%	19 $0
Q3 2023 Nov 14, 2023	BUY	$20.63 - $30.17 $144 - $211	7 New	7 $0
Q4 2022 Feb 10, 2023	SELL	$26.28 - $33.92 $262 - $339	-10 Reduced 20.0%	40 $1,000
Q3 2022 Nov 10, 2022	BUY	$25.97 - $38.53 $1,298 - $1,926	50 New	50 $2,000
Q4 2021 Feb 01, 2022	SELL	$42.59 - $55.02 $127 - $165	-3 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$48.48 - $78.23 $145 - $234	3 New	3 $0

227

119M

60.6K

48.4K

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $2.88B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

Stay updated on Quadrant Capital Group LLC with notifications on news.